ICE Bioscience is a leading drug discovery CRO with deep expertise across oncology and immuno-oncology, inflammation and autoimmunity, neuroscience, and metabolic diseases. We provide integrated support from target validation and assay development to lead optimization, in vivo pharmacology, DMPK, and preclinical candidate evaluation.
Our scientists develop immune-cell and cell-based assays to study immune activation, differentiation, cytokine release, immune-cell function, and inflammatory signaling. The platform supports research involving PBMCs, T cells, B cells, dendritic cells, NK cells, macrophages, and monocytes.
ICE Bioscience offers integrated capabilities from target-based and cell-based assay development through in vivo pharmacology and DMPK ↗. Our teams support drug discovery programs involving GLP-1R, Amylin, APJ, transporters, and other pathways relevant to diabetes, NASH, obesity, and related diseases.
We support CNS programs involving neurodegeneration, epilepsy, neuropathic pain, and mood disorders through blood–brain barrier models, neuroinflammation assays, electrophysiology, behavioral pharmacology, and translational in vivo studies.
We support oncology and immuno-oncology programs from target validation to candidate nomination across small molecules, targeted protein degraders, molecular glues, RIPTACs, ADCs, and cell-based therapeutic strategies.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
